← All trials
NCT00003418
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 1998
- Primary completion
- —
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 4400
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- International Collaborative Cancer GroupLead sponsor
- Charing Cross HospitalStudy chair
- Katholieke Universiteit LeuvenStudy chair
- UNICANCERCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- University of Nice Sophia AntipolisStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.